- Report
- November 2023
- 312 Pages
Global
From €5374EUR$5,827USD£4,350GBP
- Report
- April 2023
- 358 Pages
Global
From €4879EUR$5,292USD£3,950GBP
- Report
- July 2022
- 461 Pages
Global
From €4879EUR$5,292USD£3,950GBP
- Report
- June 2022
- 89 Pages
Global
From €764EUR$800USD£640GBP
€1527EUR$1,600USD£1,279GBP
- Report
- December 2022
- 437 Pages
Global
From €4879EUR$5,292USD£3,950GBP
- Report
- March 2023
- 71 Pages
Global
From €480EUR$539USD£416GBP
- Report
- March 2025
Global
From €400EUR$449USD£347GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- June 2022
- 86 Pages
Global
From €668EUR$700USD£560GBP
€1336EUR$1,400USD£1,119GBP
- Report
- October 2023
- 131 Pages
Global
From €4438EUR$4,650USD£3,718GBP
- Report
- March 2023
- 185 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- May 2021
- 358 Pages
Global
From €1312EUR$1,375USD£1,099GBP
€2625EUR$2,750USD£2,199GBP
- Report
- August 2022
- 180 Pages
Global
From €5726EUR$6,000USD£4,798GBP
- Report
- August 2021
- 50 Pages
United States
From €2291EUR$2,400USD£1,919GBP
- Report
- March 2021
- 240 Pages
United States
From €2863EUR$3,000USD£2,399GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more